UCR identifies new tool to kill mosquitoes
Scientists have finally found malaria’s Achilles’ heel, a neurotoxin that isn’t harmful to any living thing except Anopheles mosquitoes that spread malaria.
Nearly half the world’s population lives in areas vulnerable to malaria which kills roughly 450,000 people per year, most of them children and pregnant women. Progress fighting the disease is threatened as Anopheles develop resistance to chemical insecticides used to control them. There is also great concern about toxic side effects of the chemicals.
About 30 years ago, scientists identified a strain of bacteria that kills Anopheles. Since the bacteria’s method of attack was not understood, it couldn’t be replicated or used as an alternative to chemical insecticides — until now.
An international team led by Sarjeet Gill, distinguished professor of molecular, cell and systems biology at UC Riverside, has identified a neurotoxin produced by the bacteria, and determined how it kills Anopheles. Their work is detailed in a paper published today in Nature Communications.
It took Gill and his team 10 years to achieve a breakthrough in their quest to understand the bacteria, and Gill attributes the success to modern gene sequencing techniques. They hit the bacteria with radiation, creating mutant bacterial strains that could not produce the toxin. By comparing the nontoxic strain to the one that kills Anopheles, they found proteins in the bacteria that are the keys to toxin production.
“Identifying the mechanisms by which the bacteria targets Anopheles has not been easy,” Gill said. “We were excited not only to find the neurotoxin, called PMP1, but also several proteins that likely protect PMP1 as it’s being absorbed in the mosquito’s gut.”
Many neurotoxins generally target vertebrates, and PMP1 bears 30 percent chemical similarity to botulinum or tetanus, both highly toxic to humans. Because the neurotoxin does not affect humans, vertebrates, fish, or even other insects, Gill believes the bacteria that produce PMP1 likely co-evolved along with Anopheles mosquitoes.
“It was surprising for us that PMP1 is not toxic to mice even by injection,” Gill said.
Members of Gill’s team include postdoctoral scholars Estefania Contreras, Jianwu Chen, Harpal Dhillon, and Nadia Qureshi as well as graduate student Swati Chawla from UC Riverside, Geoffrey Masuyer and Pål Stenmark from Stockholm University and Han Lim Lee from the Institute for Medical Research in Malaysia. Their work was funded by the U.S. National Institutes of Health.
The team has applied for a patent on this discovery, and now hopes to find partners that will help them develop their bacteria-based Anopheles insecticide. These findings also open the door to new avenues of research on additional environmentally friendly insecticides.
“There is a high likelihood that if PMP1 evolved to kill the Anopheles mosquito, there are other toxins that can kill other disease-spreading pests,” Gill said. “This could just be the start of a new way to prevent hundreds of thousands from getting sick and dying every year.”
Learn more: Controlling deadly malaria without chemicals
The Latest on: Malaria
via Google News
The Latest on: Malaria
- Taiwan Liposome on go with study of inhalable malaria drug for COVID-19; shares up 32%on October 7, 2020 at 12:03 pm
Thinly traded micro cap Taiwan Liposome Company (TLC +31.7%) jumps on an 8x surge in volume in reaction to regulatory sign-offs in Australia and Taiwan to launch a Phase 1 clinical trial evaluating ...
- Togo: Malaria Consortium Expands Seasonal Malaria Chemoprevention to Togoon October 7, 2020 at 6:55 am
Malaria Consortium is pleased to announce the expansion of its seasonal malaria chemoprevention (SMC) programme to support implementation in Togo. Bringing extensive experience of SMC delivery, ...
- Nigeria: Malaria - 90% of Life-Saving Interventions Still On Track - Officialon October 7, 2020 at 1:42 am
Despite challenges posed by the COVID-19 pandemic, over 90 per cent of life-saving malaria intervention campaigns scheduled for this year are still on track.
- Taiwan Liposome secures Australian and Taiwan approval to initiate trial of inhaled malaria drug for COVID-19on October 6, 2020 at 9:35 pm
(NASDAQ:TLC) has received ethical and scientific approval from the Bellberry Human Research Ethics Committee (HREC) in Australia for its Phase I clinical trial of TLC19 Hydroxychloroquine Liposome ...
- Atomwise Receives a $2.3M Grant to Develop New Therapies for Drug Resistant Malaria and Tuberculosison October 6, 2020 at 6:14 am
The $2.3M in grant funding from the Bill & Melinda Gates Foundation will support the development of multiple global health programs to advance novel antimalarial and anti-tuberculosis small molecule ...
- Experts say Africa must scale-up malaria protection for pregnant womenon October 5, 2020 at 7:21 pm
Amidst the COVID-19 pandemic in sub-Saharan Africa, malaria - one of the world’s oldest diseases - is impacting disproportionately on pregnant women and children aged under five ...
- Understanding how the malaria parasite can withstand fever's heaton October 5, 2020 at 3:30 pm
Even when a person suffering from malaria is burning up with fever and too sick to function, the tiny blood-eating parasites lurking inside them continue to flourish, relentlessly growing and ...
- How malaria parasites withstand a fever's heaton October 5, 2020 at 1:04 pm
The parasites that cause 200 million cases of malaria each year can withstand feverish temperatures that make their human hosts miserable. Now, a Duke University-led team is beginning to understand ...
- Global Fund and Chevron: United Against HIV, TB and Malariaon October 5, 2020 at 2:47 am
English News and Press Release on Nigeria and 6 other countries about Contributions, HIV/Aids and Epidemic; published on 05 Oct 2020 by Global Fund ...
- Malaria Cases Spike In Northern Malion October 3, 2020 at 6:16 am
Malaria cases in northern Mali have spiked, according to medical workers, claiming 23 lives in the often lawless desert region last week alone.
via Bing News